A Gaucher Disease Gene Therapy Trial With FLT201

Recruiting now · Phase 3

Conditions studied: Gaucher Disease Type 1

In brief

This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT.

Key facts

Study ID
NCT07223944
Run by
Spur Therapeutics
People needed
45
Starts
2026-04-07
Expected to finish
2032-10-01
Last updated by the study team
2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.